Johnson & Johnson subsidiary Janssen has submitted a new drug application to the U.S. Food and Drug Administration seeking to market esketamine, an isomer of ketamine, as a quick-acting antidepressant for patients who have not been helped by existing antidepressant treatments.

https://www.janssen.com/janssen-submits-esketamine-nasal-spray-new-drug-application-us-fda-treatment-resistant-depression

Esketamine has already been on market since 1997 as an anesthetic, but it was only available as an injection. The new J&J formulation is a nasal spray.

How do you feel about this?